A red-hot anti-aging strategy quietly passed its first test earlier this year after 14 volunteers took drugs meant to kill off old, toxic cells in their bodies.
The small study in people with lung disease, reported in January, is being billed as the first attempt at “senolytics,” or employing drugs to clear people’s bodies of aged, toxic cells. Some researchers think this strategy could eventually be employed in healthy people to delay aging.
“This gives us to some extent a green light to go on to larger trials,” says James Kirkland, a Mayo Clinic professor who helped lead the trial, carried out in clinics in Texas and at Wake Forest University starting in 2016.
Patients took two pills that Kirkland and his colleagues believed could selectively get rid of aged cells: the leukemia drug dasatinib and a supplement called quercetin.
It is early days for drugs meant to slow aging, and some breathed a sigh of relief that patients in this first-of-a-kind study didn’t suffer serious side-effects from the drugs. “My worry is we should not leap into this too fast, because if there’s a mistake or something we don’t understand, it could set the field back,” says Judith Campisi, a professor at the Buck Institute for Research on Aging in Novato, California.
This was a pilot trial—not even in the first phase of a three-part sequence of trials needed to win approval by the US Food and Drug Administration. So, officially, it showed nothing about aging at all.
All 14 patients suffered from a fatal, hard-to-treat lung condition called idiopathic pulmonary fibrosis, which explains why they were willing to participate in the experiment. The doctors found that nine doses of the two pills over three weeks did seem to improve patients’ ability to walk a bit farther in the same amount of time, and several other measures of well-being.
A bubble of commercial enthusiasm has been building around the idea that aging could be postponed, or its effects tempered, using drug treatments. A company called Unity Biotechnology of Brisbane, California, is developing two senolytic drugs, the first of which is in a phase 1 clinical trial for osteoarthritis—it’s being injected into people’s knees. Campisi is a cofounder of Unity, and Kirkland also holds shares in the public company, which is currently worth about half a billion dollars.
Image Credit: James Kirkland, Mayo Clinic professor. Mayo Clinic
News This Week
DNA Script has raised $38.5 million in new financing to commercialize a process that it claims is the first big leap forward in manufacturing genetic material. The revolution in synthetic biology that’s reshaping industries [...]
These startups have seen investment from NEA, Andreessen Horowitz, and DARPA, among many others. As the digital health sector matures from basic tracking apps into highly regulated medical devices, we are seeing bleeding edge [...]
Quantum technologies utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing. However [...]
Nanoparticles can be used in many ways as catalysts. To be able to tailor them in such a way that they can catalyse certain reactions selectively and efficiently, researchers need to determine the properties [...]
University of Copenhagen researchers have developed a nanocomponent that emits light particles carrying quantum information. Less than one-tenth the width of a human hair, the miniscule component makes it possible to scale up [...]
Once cartilage is damaged, there is little that can be done to repair it. Unlike many other tissues, cartilage doesn’t heal well and consequences of injuries and disease can last a lifetime. Now [...]
Bacteria across our planet contain nanometer-sized factories that do many different things. Some make nutrients, others isolate toxic materials that could harm the bacteria. We have barely scratched the surface of their functional diversity. [...]
“We’ll have nanobots that… connect our neocortex to a synthetic neocortex in the cloud. Our thinking will be a…. biological and non-biological hybrid.” Ray Kurzweil, TED 2014 UPDATE - May 2 2019 Since [...]
Researchers from University of Jyväskylä and Aalto University in Finland have developed a customized DNA nanostructure that can perform a predefined task in human body-like conditions (ACS Nano, "Reconfigurable DNA Origami Nanocapsule for pH-Controlled [...]
Some of the most famous scientific discoveries happened by accident. From Teflon and the microwave oven to penicillin, scientists trying to solve a problem sometimes find unexpected things. This is exactly how we created [...]
When diagnosed with a disease, it's often overwhelming to sort through mountains of medical data to figure out what therapies are available, pinpoint where they're offered and identify the best experts to help. Complexity [...]
The NanoMedicines Innovation Network (NMIN) has been awarded $18.5 million in new funding from the Networks of Centres of Excellence (NCE), a federal program that connects teams of scientists across Canada to collaborate on [...]
Young researchers from Siberian Federal University (SibFU) along with their colleagues from FRC KSC SB RAS are designing a technology for producing multilayer gilded nanodisks for targeted drug delivery and treating cancer using dip [...]
Frank Boehm: Publication of our new paper “Human Brain/Cloud Interface” in Frontiers in Neuroscience
Contributors: Nuno R. B. Martins, Amara Angelica, Yuriy Svidinenko, Frank J. Boehm, Ioan Opris, Mikhail A. Lebedev, Melanie Swan, Steven A. Garan, Jeffrey V. Rosenfeld, Tad Hogg, Robert A. Freitas Jr. et al Excerpt [...]
Abstract The progressive growth in nanotechnology approaches to diagnostics and therapeutics, especially for cancer, necessitates training physicians in nanoethics. This article explains why it is critical for medical education to include instruction in [...]